Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

PURPOSE: VEGF is upregulated in glioblastoma and may contribute to immunosuppression. We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent glioblastoma. PATIENTS AND METHODS: Eighty bevacizumab-naïve patients with recurrent glioblastoma were randomized to pembrolizum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Nayak, Lakshmi, Molinaro, Annette M., Peters, Katherine, Clarke, Jennifer L., Jordan, Justin T., de Groot, John, Nghiemphu, Leia, Kaley, Thomas, Colman, Howard, McCluskey, Christine, Gaffey, Sarah, Smith, Timothy R., Cote, David J., Severgnini, Mariano, Yearley, Jennifer H., Zhao, Qing, Blumenschein, Wendy M., Duda, Dan G., Muzikansky, Alona, Jain, Rakesh K., Wen, Patrick Y., Reardon, David A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8284901/
https://ncbi.nlm.nih.gov/pubmed/33199490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2500
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge